普米克联合硫酸沙丁胺醇雾化吸入剂治疗喘憋型肺炎效果观察  

Observation on the Efficacy of Pulmicort and Salbutamol Sulfate Nebulization Inhalant in the Treatment of Asthmatic Pneumonia

作　　者：赵梁育 张丽 单秋歌 Zhao Liang-yu;Zhang Li;Shan Qiu-ge(The Second Affliated Hospital of Luohe Medical College,Luohe,Henan 462300,China)

机构地区：[1]漯河医专二附院,河南漯河462300

出　　处：《中国合理用药探索》2019年第1期136-138,共3页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨普米克联合硫酸沙丁胺醇雾化吸入剂治疗喘憋型肺炎的效果。方法:选取2015年6月—2017年5月我院收治的160例喘憋型肺炎患儿为研究对象,按随机数字表法分为对照组和观察组,各80例。对照组给予对症、常规等综合治疗,观察组在对照组基础上加用普米克(体质量大于10 kg患儿给予1000μg;体质量小于10 kg患儿给予600μg,雾化吸入,2～4次/d)联合硫酸沙丁胺醇雾化吸入剂(体质量大于10 kg患儿给予0.5 mL;体质量小于10 kg患儿给予0.25 mL,雾化吸入,2～4次/d)治疗,比较两组临床疗效、临床症状消失时间以及不良反应发生情况。结果 :观察组治疗显效率及总有效率均显著高于对照组,差异有统计学意义(P <0.05);观察组喘憋、咳嗽、喘鸣音及干湿啰音、肺部阴影消失时间显著短于对照组,差异有统计学意义(P <0.05);观察组不良反应发生率显著低于对照组,差异有统计学意义(P <0.05)。结论:普米克联合硫酸沙丁胺醇雾化吸入剂治疗喘憋型肺炎效果显著,能快速缓解临床症状,且安全可靠,值得临床推广使用。Objective:To investigate the effcacy of pulmicort and salbutamol sulfate nebulization inhalant in the treatment of asthmatic pneumonia.Methods:160 children with asthmatic pneumonia admitted to our hospital from June 2015 to May 2017 were selected as subjects investigated and divided into a control group and an observation group according to the random number table method,80 cases in each group.The patients in the control group were given symptomatic and conventional treatment and other comprehensive treatment,and the patients in the observation group were given pulmicort(1000μg for children with body mass greater than 10 kg;600μg for children with body mass less than 10 kg,nebulization inhalation,2~4 times/d)combined with salbutamol sulfate nebulization inhalant(0.5 mL for children with body mass greater than 10 kg;0.25 mL for children with body mass less than 10 kg,nebulization inhalation,2~4 times/d)on the basis of the control group.The clinical efficacy,the disappearance time of clinical symptoms and the occurrence of adverse reactions were compared between the two groups.Results:The markedly effective rate and total effective rate in the observation group were significantly higher than those in the control group,with statistically significant difference(P<0.05).The disappearance time of wheezing,cough,wheezing sound,dry and wet rales and lung shadow in the observation group was shorter than that in the control group,with statistically significant difference(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group,with statistically significant difference(P<0.05).Conclusion:Pulmicort combined with salbutamol sulfate nebulization inhalant is effective in the treatment of asthmatic pneumonia,which can quickly relieve clinical symptoms,and is safe and reliable and worthy of clinical promotion.

关 键 词：普米克 硫酸沙丁胺醇雾化吸入剂 喘憋型肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]